AUR1545

AUR1545 is a potent and selective small molecule degrader of the histone acetyltransferases KAT2A (lysine acetyltransferase 2A) and KAT2B (lysine acetyltransferase 2B). Developed by Auron Therapeutics, it was designed to target epigenetic regulators that are hijacked in cancer cells to maintain a highly plastic and proliferative state. By inducing rapid and selective degradation of KAT2A/B, AUR1545 inhibits tumor growth and promotes differentiation in preclinical models of acute myeloid leukemia (AML), small cell lung cancer (SCLC), and neuroendocrine tumors. The compound demonstrates high selectivity, picomolar potency for its targets, oral bioavailability, and significant anti-proliferative effects in vivo[1][3][4][5].